Prognostic significance of syndecan-1 expression in cervical cancers

Journal of Gynecologic Oncology

Volumn 22, Issue 3, 2011, Pages 161-167

  Kim, Yu Im ^a   Lee, Ahwon ^a   Lee, Bum Hee ^a   Kim, Su Young ^a  

^a The Catholic University of Korea College of Medicine   (South Korea)

Author keywords

Carcinoma; DNA copy number variations; Gene expression; Squamous cell; Syndecan 1; Uterine cervical neoplasms

Indexed keywords

SYNDECAN 1;

ARTICLE; CANCER GRADING; CANCER SURVIVAL; COPY NUMBER VARIATION; FLUORESCENCE IN SITU HYBRIDIZATION; GENE EXPRESSION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; PROGNOSIS; UTERINE CERVIX CANCER;

EID: 80052977088     PISSN: 20050380     EISSN: 20050399     Source Type: Journal    
DOI: 10.3802/jgo.2011.22.3.161     Document Type: Article

References (29)

1. Moody CA, Laimins LA. Human papillomavirus oncoproteins: pathways to transformation. Nat Rev Cancer 2010;10:550-60.
2. Cappellen D, De Oliveira C, Ricol D, de Medina S, Bourdin J, Sastre-Garau X, et al. Frequent activating mutations of FGFR3 in human bladder and cervix carcinomas. Nat Genet 1999;23:18-20.
3. Alberts B, Johnson A, Lewis J, Raff M, Roberts K, Walter P. Molecular biology of the cell. 5th ed. New York: Garland Science; 2008.
4. Rapraeger AC. Molecular interactions of syndecans during development. Semin Cell Dev Biol 2001;12:107-16.
5. Bernfield M, Gotte M, Park PW, Reizes O, Fitzgerald ML, Lincecum J, et al. Functions of cell surface heparan sulfate proteoglycans. Annu Rev Biochem 1999;68:729-77.
6. Inki P, Jalkanen M. The role of syndecan-1 in malignancies. Ann Med 1996;28:63-7.
7. Matsumoto A, Ono M, Fujimoto Y, Gallo RL, Bernfield M, Kohgo Y. Reduced expression of syndecan-1 in human hepatocellular carcinoma with high metastatic potential. Int J Cancer 1997;74:482-91.
8. Kumar-Singh S, Jacobs W, Dhaene K, Weyn B, Bogers J, Weyler J, et al. Syndecan-1 expression in malignant mesothelioma: correlation with cell differentiation, WT1 expression, and clinical outcome. J Pathol 1998;186:300-5.
9. Nackaerts K, Verbeken E, Deneffe G, Vanderschueren B, Demedts M, David G. Heparan sulfate proteoglycan expression in human lung-cancer cells. Int J Cancer 1997;74:335-45.
10. Oh JH, Kim JH, Ahn HJ, Yoon JH, Yoo SC, Choi DS, et al. Syndecan-1 enhances the endometrial cancer invasion by modulating matrix metalloproteinase-9 expression through nuclear factor kappaB. Gynecol Oncol 2009;114:509-15.
11. Davies EJ, Blackhall FH, Shanks JH, David G, McGown AT, Swindell R, et al. Distribution and clinical significance of heparan sulfate proteoglycans in ovarian cancer. Clin Cancer Res 2004;10:5178-86.
12. Conejo JR, Kleeff J, Koliopanos A, Matsuda K, Zhu ZW, Goecke H, et al. Syndecan-1 expression is up-regulated in pancreatic but not in other gastrointestinal cancers. Int J Cancer 2000;88:12-20.
13. Wang H, Leavitt L, Ramaswamy R, Rapraeger AC. Interaction of syndecan and alpha6beta4 integrin cytoplasmic domains: regulation of ErbB2-mediated integrin activation. J Biol Chem 2010;285:13569-79.
14. Roh YH, Kim YH, Choi HJ, Lee KE, Roh MS. Syndecan-1 expression in gallbladder cancer and its prognostic significance. Eur Surg Res 2008;41:245-50.
15. Inki P, Stenback F, Grenman S, Jalkanen M. Immunohistochemical localization of syndecan-1 in normal and pathological human uterine cervix. J Pathol 1994;172:349-55.
16. Ishikawa T, Kramer RH. Sdc1 negatively modulates carcinoma cell motility and invasion. Exp Cell Res 2010;316:951-65.
17. Couchman JR. Syndecans: proteoglycan regulators of cellsurface microdomains? Nat Rev Mol Cell Biol 2003;4:926-37.
18. Numa F, Hirabayashi K, Kawasaki K, Sakaguchi Y, Sugino N, Suehiro Y, et al. Syndecan-1 expression in cancer of the uterine cervix: association with lymph node metastasis. Int J Oncol 2002;20:39-43.
19. Hasengaowa, Kodama J, Kusumoto T, Shinyo Y, Seki N, Hiramatsu Y. Prognostic significance of syndecan-1 expression in human endometrial cancer. Ann Oncol 2005;16:1109-15.
20. Loussouarn D, Campion L, Sagan C, Frenel JS, Dravet F, Classe JM, et al. Prognostic impact of syndecan-1 expression in invasive ductal breast carcinomas. Br J Cancer 2008;98:1993-8.
21. Zellweger T, Ninck C, Mirlacher M, Annefeld M, Glass AG, Gasser TC, et al. Tissue microarray analysis reveals prognostic significance of syndecan-1 expression in prostate cancer. Prostate 2003;55:20-9.
22. Jilani I, Wei C, Bekele BN, Zhang ZJ, Keating M, Wierda W, et al. Soluble syndecan-1 (sCD138) as a prognostic factor independent of mutation status in patients with chronic lymphocytic leukemia. Int J Lab Hematol 2009;31:97-105.
23. Joensuu H, Anttonen A, Eriksson M, Makitaro R, Alfthan H, Kinnula V, et al. Soluble syndecan-1 and serum basic fibroblast growth factor are new prognostic factors in lung cancer. Cancer Res 2002;62:5210-7.
24. Mahtouk K, Hose D, Raynaud P, Hundemer M, Jourdan M, Jourdan E, et al. Heparanase influences expression and shedding of syndecan-1, and its expression by the bone marrow environment is a bad prognostic factor in multiple myeloma. Blood 2007;109:4914-23.
25. Mathe M, Suba Z, Nemeth Z, Tatrai P, Fule T, Borgulya G, et al. Stromal syndecan-1 expression is an adverse prognostic factor in oral carcinomas. Oral Oncol 2006;42:493-500.
26. Juuti A, Nordling S, Lundin J, Louhimo J, Haglund C. Syndecan-1 expression: a novel prognostic marker in pancreatic cancer. Oncology 2005;68:97-106.
27. Watari J, Saitoh Y, Fujiya M, Shibata N, Tanabe H, Inaba Y, et al. Reduction of syndecan-1 expression in differentiated type early gastric cancer and background mucosa with gastric cellular phenotype. J Gastroenterol 2004;39:104-12.
28. Rintala M, Inki P, Klemi P, Jalkanen M, Grenman S. Association of syndecan-1 with tumor grade and histology in primary invasive cervical carcinoma. Gynecol Oncol 1999;75:372-8.
29. Shinyo Y, Kodama J, Hasengaowa, Kusumoto T, Hiramatsu Y. Loss of cell-surface heparan sulfate expression in both cervical intraepithelial neoplasm and invasive cervical cancer. Gynecol Oncol 2005;96:776-83.